Increased AP-1 activity in drug resistant human breast cancer MCF-7 cells

Breast Cancer Research and Treatment

Volumn 53, Issue 3, 1999, Pages 229-240

  Daschner, Phillip J ^b   Ciolino, Henry P ^a   Plouzek, Cathie A ^a   Yeh, Grace Chao ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c Cellular Defense Section   (United States)

Author keywords

AP 1; MCF 7 cells; MDR1; Multidrug resistance

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; LUCIFERASE; MESSENGER RNA; TRANSCRIPTION FACTOR AP 1;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA BINDING; ELECTROPHORETIC MOBILITY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MULTIDRUG RESISTANCE; OLIGONUCLEOTIDE PROBE; ONCOGENE C FOS; ONCOGENE C JUN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSACTIVATION;

BLOTTING, WESTERN; BREAST NEOPLASMS; CELL NUCLEUS; DNA; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; GENE EXPRESSION; HUMANS; P-GLYCOPROTEIN; PACLITAXEL; PROMOTER REGIONS (GENETICS); PROTO-ONCOGENE PROTEINS C-FOS; PROTO-ONCOGENE PROTEINS C-JUN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TRANSCRIPTION FACTOR AP-1; TUMOR CELLS, CULTURED; UP-REGULATION; VINBLASTINE;

EID: 0032920661     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006138803392     Document Type: Article

References (57)

1. Ueda K, Cardarelli C, Gottesman MM, Pastan I: Expression of a full length cDNA for the human MDR1 gene confers resistance to colchicine, doxorubicin and vinblastine. Proc Natl Acad Sci USA 84: 3004-3008, 1987
2. Pastan I, Gottesman MM, Udea K, Lovelace E, Rutherford AV, Willingham MC: A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc Natl Acad Sci USA 85: 4480-4490, 1988
3. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM, Pastan I: Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989
4. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J, Ling V: Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817-819, 1985
5. Shen DW, Fojo AT, Roninson IB, Chin JE, Richert N, Pastan I, Cottesman MM: Human multidrug-resistant cell lines: Increased MDR1 expression can precede gene amplification. Science 232: 643-645, 1986
6. Utica K, Paslan I, Gottesman MM: Isolation and sequence of the promoter region of the human multidrug resistance (P-glycoprotein) gene. J Biol Chem 262: 17432-17436, 1987
7. Burt RK, Thorgeirsson SS. Coinduction of MDR1 multidrug-resistance and cytochrome P-450 genes in rat liver by xenobiotics. J Natl Cancer Inst 80: 1343-1386, 1988
8. Cornwell MM: The human multidrug resistance gene: Sequences upstream and downstream of the initiation site influence transcription. Cell Growth Differ 1: 607-615, 1990
9. Kohno K, Tanimura H, Sato S, Nakayama Y, Makino Y, Wada M, Fojo AT, Kuwano M: Cellular control of human multidrug resistance 1 (MDR1) gene expression in ahsence and presence of gene amplification in human cancer cells. J Biol Chem 269: 20503-20508, 1994
10. Madden MJ, Morrow CS, Nakagawa M, Goldsmith ME, Fairchild CF, Cowan KH: Identification of 5′ and 3′ sequences involved in the regulation of transcription of the human MDR1 gene in vivo. J Biol Chem, 268: 8290-8297, 1993
11. Goldsmith ME, Madden MJ, Morrow CS, Cowan KH: A Y-box consensus sequence is required for basal expression of the human multidrug resistance (MDR1) gene. J Biol Chem 268: 5856-5860, 1993.
12. Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, Kuwano M, Kohno K: Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56: 4224-4228, 1996
13. Chin KV, Tanaka S, Darlington G, Pastan I, Gottesman MM: Heat shock and arsenite increase expression of the multidrug resistance (MDR1) gene in human carcinoma cells. J Biol Chem 265: 221-226, 1990
14. Bates SE, Mickley LA, Chen YN, Richert N, Rudick J, Biedler JL, Fojo AT: Expression of a drug resistance gene in human reuroblastoma cell lines: Modulation by retinoic acid-induced differentiation. Mol Cell Biol 9: 4337-4344, 1989
15. Uchiumi T, Dohno K, Tanimura H, Matsuo K, Sato S, Uchida Y, Kuwano M: Enhanced expression of the human multidrug resistance I gene in response to UV light irradiation. Cell Growth Differ 4: 147-157, 1993
16. Kohno K, Sato S, Takano H, Matsuo K, Kuwano M: The direct activation of human multidrug resistance gene (MDR1) by anticancer agents. Biochem Biophys Res Commun 165: 1415-1421, 1989
17. Cornwell MM, Smith DE: SP-1 activates the MDR1 promoter through one of two distinct GC-rich regions that modulate promoter activity. J Biol Chem 268: 19505-19511, 1993
18. Glazer RI, Rohlff C: Transcriptional regulation of multidrug resistance in breast cancer. Breast Cancer Res Treat 31: 263-271, 1994
19. Kohno K, Sato S, Uchiumi T, Takano H, Kato S, Kuwano M: Tissue-specific enhancer of the human multidrug resistance (MDR1) gene. J Biol Chem 265: 19690-19696, 1990
20. Combates NJ, Rzepka RW, Chen YP, Cohen D: NF-IL6, a member of the C/EBP family of transcription factors, binds and trans-activates the human MDR1 gene promoter. J Biol Chem 269: 29715-29719, 1994
21. Chin KV, Ueda K, Paslan I, Gottesman MM: Modulation of activity of the promoter of the human MDR1 gene by Ras and p53. Science 255: 459-462, 1992
22. Goldsmith ME, Gudas JM, Schneider E, Cowan KH: Wild type p53 stimulates expression from the human multidrug resistance promoter in a p53-negative cell line. Biol Chem 270, 1894-1898, 1995
23. McCoy C, Smith DE, Cornwell MM: 12-O-tetradecanoylphorbol-13-acetate activation of the MDR1 promoter is mcdiated by EGR1. Mol Cell Biol 15: 6100-6108, 1995
24. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, Jonat C, Herrlich P, Karin M: Phorbol ester-inducible genes contain a common cis element recognized by TPA-modulated trans-acting factor. Cell 49: 729-739, 1987
25. Angel P, Karin M: The role of Jun, Fos and the AP-1 complex in cell proliferation and transformation. Biochim Biophys Acta 1072: 129-157, 1991
26. Ogura M, Takatori T, Sugimoto Y, Tsuruo T: Identifcation and characterization of three DNA-binding proteins on the promoter of the human MDR1 gene in drug-sensitive and resistant cells. Jpn J Cancer Res 82: 1151-1159, 1991
27. Ritke MK, Bergoltz VV, Allan WP, Yalowich JC: Increased c- jun/AP-1 levels in etoposide-resistant human leukemia K562 cells. Biochem Pharmacol 48: 525-533, 1994
28. Bhushan A, Abramson R, Chiu JK, Tritton TR: Expression of c-fos in human and murine multidrug-resistant cells. Mol Pharmacol 42: 69-74, 1992
29. Yu R, Shtil AA, Tan TH, Roninson IB, Kong AT: Adriamycin activates c-Jun N-terminal kinase in human leukemia cells: A relevance to apoptosis. Cancer Lett 107: 73-81, 1996
30. Chaudhary PM, Roninson IB: Activation of MDR1 (P-glycoprotein) gene expression in human cells by protein kinase agonists. Oncol Res 4: 281-290, 1992
31. Kim SH, Lee SH, Kwak NH, Kang CD, Chung BS: Effects of the activated Raf protein kinase on the human multidrug resistance I (MDR1) gene promoter. Cancer Lett 98: 199-205, 1996
32. Burt RK, Garfield S, Johnson K, Thorgeirsson SS: Transformation of rat liver epithelial cells with v-H-ras or v-raf causes expression of MDR1, glutathionc-S-transferasc-P and increased resistance to cytotoxic chemicals. Carcinogenesis 9: 2329-2332, 1988
33. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC: Cellular localization of the multidrug resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA 84: 7735-7738, 1987
34. Yeh GC, Lopaczynska J, Poore CM, Phang JM: A new functional role for P-glycoprotein: efflux pump for benzo(a)pyrene in human breast cancer MCF-7 cells. Cancer Res 52: 6692-6695, 1992
35. van Asperen J, Schinkel AH, Beijnen JH, Nooijen WJ, Borst P. van Tellingen O: Altered pharmacokinetics of vinblastine in Mdrla P-glycoprotein-deficient mice. J Natl Cancer Inst 88: 994-999, 1996
36. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, Boyd MR: New colormetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107-1112, 1990
37. Berger SL, Chirgwin JM: Isolation of RNA. Methods Enzymol 180: 3-13, 1989
38. Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I. Gottesman MM, Roninson IB: Internal duplication and homology with bacterial transport proteins in the MDR1 (P-glycoprotein) gene from multidrug resistant human cells. Cell 47: 381-389, 1986
39. Alani R, Brown P, Binetruy B, Dosaka H, Rosenberg RK, Angel P, Karin M, Birrer M: The transactivating domain of the c-Jun proto-oncoprotein is required for cotransformation of rat embryo cells. Mol Cell Biol 11: 6286-6295, 1991
40. Brown PH, Chen TK, Birrer MJ: Mechanism of action of a dominant-negative mutant of c-jun. Oncogene 8: 791-799, 1993
41. Sambrook J, Fritsch EF, Maniatis TE (eds): Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY; Cold Spring Harbor Laboratory, 1989
42. Ryseck RP, Bravo R: c-Jun, Jun B, and Jun D differ in their binding affinities to AP-1 and CRE consensus sequences: Effects of Fos proteins. Oncogene 6: 533-542, 1990
43. Sanger F, Nicklen S, Coulson AR: DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci 74: 5463-5467, 1977
44. Rosenthal N: Identification of regulatory elements of cloned genes with functional assays. Methods Enzymol 152: 704, 1987
45. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976
46. Dignam JD, Lebowitz RM, Roeder RG: Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11: 1475-1489, 1983
47. Oda Y, Rosek I, Radig K, Wagemann W, Mittler U, Roessner A: Expression of MDR1/P-glycoprotein and multidrug resistance-associated protein in childhood solid tumors. Virchows Arch 430: 99-105, 1997.
48. Phang JM, Poore MC, Lopaczynska J, Yeh GC: Flavanol-stimulated efflux of 7,12-dimethylbenzanthracene in multidrug resistant breast cancer cells. Cancer Res 53: 5977-5981, 1993
49. Owen TA, Bortell R, Yocum SA, Smock S, Zhang M, Abate C, Shalhoub V, Aronin N, Wright KL, VanWijnen AJ, Stein JI, Curran T, Lian JB, Stein GS: Coordinate occupancy of AP-1 sites in the vitamin D-responsive and CCAAT box elements by Fos-Jun in the osteocalcin gene; model for I-or phenotype suppression of transcription. Proc Natl Acad Sci 87: 9990-9994, 1990
50. Masquiller D, Sassone-Corsi P: Transcriptional cross-talk: nuclear factors CREM and CREB bind AP-1 sites and inhibit activation by c-jun. J Biol Chem 267: 22460-22466, 1992
51. Gant TW, Silverman JA, Thorgeirsson SS: Regulation of P-glycoprotein gene expression in hepatocyte cultures and liver cells by a trans-acting transcriptional repressor. Nucleic Acids Res 20: 2841-2846, 1992
52. Yu L, Cohen D, Piekarz RL, Horwitz SB: Three distinct nuclear protein binding sites in the promoter of the murine multidrug resistance MDR1 b gene. J Biol Chem 268: 7520-7526, 1993
53. Teeter LD, Eckersberg T, Tsai Y, Kuo MT: Analysis of the Chinese hamster P-glycoprotein/multidrug resistance gene pgp 1 reveals that the AP-1 site is essential for full promoter activity. Cell Growth Differ 2: 429-437, 1991
54. Ritke MK, Yalowich JC: Altered gene expresion in human leukemia K562 cells selected for resistance to etoposide. Biochem Pharmacol 46: 2007-2020, 1993
55. Chen TK, Smith LM, Gebhardt DK, Birrer MJ, Brown PH: Activation and inhibition of the AP-1 complex in human breast cancer cells. Mol Carcinogen 15: 215-226, 1996
56. Rohlff C, Safa B, Rahman A, Cho-Chung YS, Klecker RW, Glazer RI: Reversal of resistance to Adriamycin by 8-CI-cAMP in adriamycin resistant HL-60 leukemia cells is associated with reduction of type I cAMP-dependent protein kinase and cAMP response element binding protein DNA binding activity. Mol Pharmacol 43: 372-379, 1993
57. Cornwell MM, Smith DE: A signal transduction pathway for activation of the MDR1 promoler involves the prolooncogene c-raf kinasc. J Biol Chem 268: 15347-15350, 1993